28 results about "Peptide expression" patented technology

To provide an inhibitor for suppressing expression of an antibacterial peptide in brown planthopper and an application thereof.SOLUTION: A dsNlPCE4 inhibitor designed based on the NlPCE4 gene of the brown planthopper is obtained. The inhibitor, when applied to brown planthoppers inoculated on their body surface with Metarhizium anisopliae, significantly increases the mortality of the brown planthopper. The present invention combines two technical strategies for pest control, biocontrol fungi and RNA interference (RNAi), to provide a new target for brown planthopper control technology based on cooperative mediation of RNAi.SELECTED DRAWING: Figure 5

The invention relates to an artificial nucleic acid molecule comprising at least one 5′ UTR element which is derived from a TOP gene, at least one open reading frame, and preferably at least one histone stem-loop. Optionally the artificial nucleic acid molecule may further comprise, e.g. a poly(A)sequence, a poyladenylation signal, and / or a 3′ UTR. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and / or genetic vaccination.

The invention relates to a novel application of a compound, in particular to an application of piceatannol in preparation of an animal host defense peptide expression promoter. The invention provides an application of piceatannol in preparation of a host defense peptide expression promoter, wherein piceatannol shown in a formula I or a derivative thereof is used as a pharmacodynamic active component to prepare the host defense peptide expression promoter in a required dosage form. The piceatannol improves the animal immune function by inducing host endogenous defense peptide expression, is not prone to causing bacterial drug resistance, can be developed into a novel feed additive, replaces antibiotics and meets the requirements of modern animal husbandry.

Disclosed are a synthesis system for a multi-copy peptide without redundant sequences, and a use. The synthesis system comprises a synthetic expression vector, wherein the synthetic expression vector comprises a tag-(linker-target polypeptide)n, n=1-10, n represents the number of copies, and the tag has an amino acid sequence selected from KPYDGP, KSKGEE, MTMITDSLAVVLQ, GFILGFIL or HHHHHH. The fusion tag enhances the expression of multi-copy polypeptides and results in a higher theoretical yield of the target polypeptide.

The present invention relates to a method for producing a collagen peptide preparation containing recombinant collagen peptides. The method is characterized in that it comprises the following steps: a) providing an in vitro expression system including at least one expression cassette, the expression cassette including at least one nucleotide sequence encoding a collagen peptide having a molecular weight in the range of 8 to 100 kDa; b) incubating the expression system under conditions that allow expression of the collagen peptide; c) obtaining the collagen peptide; d) hydrolyzing the collagen peptide under conditions that result in the production of a collagen peptide preparation including collagen peptides having an average molecular weight of 1 to 5 kDa and a molecular weight in the range of 0.1 to 12 kDa; wherein no more than 5.5% by weight of the hydrolyzed collagen peptides have a molecular weight of less than 500 Da, no more than 2.8% by weight of the hydrolyzed collagen peptides have a molecular weight between 7500 Da and 13500 Da, and between 35% and 60% by weight of the hydrolyzed collagen peptides have a molecular weight between 1500 Da and 3500 Da; e) obtain the collagen peptide preparation.

The present invention relates to a recombinant bacterium producing Arctic-derived β-glucosidase and its application, belonging to the field of biotechnology. The target gene of the recombinant bacterium is β-glucosidase derived from Arctic bacteria Arc12, the nucleotide sequence of which is shown in SEQ ID No: 1, and the nucleotide sequence of the β-glucosidase with signal peptide is shown in SEQ ID No: 2, the signal peptide is Bacillus subtilis signal peptide CitH, and the expression vector is Escherichia coli-Bacillus shuttle plasmid pMA5, which contains constitutive promoter P HpaII The expression strain is Bacillus subtilis WB600. The present invention provides a method for secretory expression of the enzyme under specific promoter, signal peptide, and strain conditions. This method is simple to operate and can be achieved without the need for special inducers. Secretory expression of the enzyme eliminates the need for cell disruption in downstream processing, reducing production costs and possessing promising application prospects.

The invention provides an oligopeptide, and a lentiviral expression vector and a recombinant cell for expressing the oligopeptide. The invention further provides application of the compound in tumor treatment. After the oligopeptide is delivered to HT1080 cells through a lentivirus system, the intracellular SLC7A11 protein level is reduced, the intracellular Fe < 2 + > and lipid peroxidation level is remarkably increased, and the oligopeptide has a remarkable inhibition effect on cell proliferation and has the tumor treatment potential.

Disclosed are methods and compositions for enhanced expression of a heterologous polypeptide of interest in an organism. The methods generally comprise first transforming the organism with a genetic construct having a heterologous polypeptide of interest and amplifying expression of the polypeptide through in vivo gene amplification.

The present invention relates to nucleic acid constructs comprising a first polynucleotide encoding a signal peptide from a bacterial alpha-amylase a second polynucleotide encoding a polypeptide having hexosaminidase activity; expression vectors and host cells comprising said nucleic acid constructs; and methods for producing polypeptides having hexosaminidase activity.

The invention discloses a method for transforming citrus by using a drosophila Drosocin gene to induce antibacterial peptide expression resistance to citrus huanglongbing, and relates to the technical field of forest breeding and seedling raising, the method comprises the following steps: introducing the drosophila Drosocin gene into a citrus receptor material, and inducing Drosocin antibacterial peptide expression to obtain a citrus huanglongbing-resistant citrus material, and the nucleotide sequence of the drosophila Drosocin gene is as shown in SEQ ID NO: 1. According to the invention, the Drosocin gene is introduced into a citrus receptor material to induce the expression of Drosocin antibacterial peptide, so as to obtain a citrus material capable of resisting Candidatus Liberobacter asiaticum, thereby achieving the purposes of inhibiting the proliferation of Candidatus Liberobacter asiaticum and providing a green and efficient Candidatus Liberobacter asiaticum prevention and control means.

This invention provides recombinant polynucleotides comprising nucleic acids encoding CYP76AD6 or related genes, and their use for the production of L-DOPA from tyrosine and for the treatment of dopamine-responsive disorders such as Parkinson's disease. This invention also provides recombinant polynucleotides comprising nucleic acids encoding CYP76AD1 and / or CYP76AD6, nucleic acids encoding DOPA 4,5-dioxygenase (DOD) such as beet DODA1, and in some cases, nucleic acids encoding betaine-related glucosyltransferases such as the four o'clock gene cyclic-DOPA 5-O-glucosyltransferase (cDOPA5GT), and their use for the production of betaine. Finally, this invention provides chimeric polypeptides, expression vectors, cells, compositions, and organisms (including plants), and their use in the various methods of this invention.

The present application relates to the field of agricultural biotechnology, in particular to locust immune related protein LmEaster gene and application thereof. The present application clones LmEaster gene and synthesizes double-stranded RNA, adopts injection method to treat locusts, and detects the mortality of locusts in each treatment and the expression amount change of related antibacterial peptide, and confirms that after interfering with LmEaster gene of locusts, the expression amount of antibacterial peptide of locusts is increased, the immune defense ability of locusts is increased, and then the mortality is reduced.

A novel micropeptide, MP36, and its applications are provided. This MP36 micropeptide can be used to prepare reagents or drugs for the detection, prevention, or treatment of tumors, including one or more of lung cancer, breast cancer, colon cancer, glioma, bladder cancer, gastric cancer, head and neck cancer, and sarcoma. In tumors, the MP36 micropeptide can inhibit tumor cell growth and / or metastasis by specifically inhibiting MP36 expression via small interfering RNA; or by overexpressing MP36 to inhibit tumor cell growth and / or metastasis; or by conjugating a membrane-penetrating peptide to inhibit tumor growth and / or metastasis. It has significant value for new drug development and tumor detection.

The invention provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD6 or related gene and their use for producing L-DOPA from tyrosine. The invention also provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD1 and / or CYP76AD6, a nucleic acid encoding a DOPA 4,5-dioxygenase (DOD) enzyme, such as Beta vulgaris DODA1, and, in some cases, a nucleic acid encoding betalain related glucosyltransferase, such as Mirabilis jalapa gene cyclo-DOPA 5-O-glucosyltransferase (cDOPA5GT), and their use for producing betalains. Finally, the invention provides chimeric polypeptides, expression vectors, cells, compositions, and organisms, including plants, and their uses in various methods of the invention.

The invention discloses a preparation method of a high-loading-capacity brain-targeting-enhanced exosome, a product and application, and belongs to the technical field of biological medicine. The invention aims to solve the technical problems of low targeting peptide expression quantity, insufficient loading rate, poor targeting efficiency, weak blood brain barrier penetrating power and the like in the existing exosome targeting modification technology. According to the technical scheme, the method is characterized in that the concentration ratio of DBCO-NHS to T7 to exosome is optimized, and the high loading rate is achieved through a two-step loading system.

This document relates to non-human animal models (e.g., non-human mammalian models such as mouse models) for aging (e.g., neural aging). For example, non-human animal models having reduced or eliminated levels of aralkylamine N-acetyltransferase (AANAT) polypeptide expression are provided.

The invention relates to an engineering strain for intestinal delivery of a GLP-1 / GIP dual-receptor stimulant and application thereof, the strain takes uracil nutrition deletion type saccharomyces boulardii as a chassis strain, and a polypeptide expression module is integrated in a genome of the chassis strain; the polypeptide expression module comprises a secretory signal peptide coding sequence and a polypeptide coding sequence fused with the secretory signal peptide coding sequence, and the polypeptide coding sequence codes polypeptide formed by connecting a plurality of glucagon-like peptide-1 repetitive units and a plurality of glucose-dependent insulinotropic polypeptide repetitive units in series; restriction enzyme cutting sites which can be cut by yeast endogenous protease are arranged between the adjacent repeating units, so that the polypeptide is cut in a Golgi apparatus or a secretion processing process, and mature GLP-1 agonist and GIP agonist are released. The strain can be orally taken, can continuously control the delivery of GLP-1 / GIP dual agonists in an accurate dosage manner, so that the obesity and metabolic disorder are effectively improved, and the administration compliance and safety are improved.

The invention relates to the technical field of medicinal breeding of special insects, in particular to a method for improving zinc absorption and anti-inflammatory components of maggots, which comprises the following steps: preparing bullfrog-poria cocos-herba epimedii fermented feed; on the basis of the fermented feed, three-generation continuous directional feeding and screening are carried out on maggots, low zinc stress is applied to the first generation, individuals with optimized zinc transport related capacity are screened, LPS inflammation stress is applied to the second generation, and individuals with optimized anti-inflammation related capacity are screened. Applying drying stress to the third generation, and screening the individuals with the zinc content and the anti-inflammatory peptide expression quantity reaching the standard; through the three generations of screening, a maggot population with stable zinc content and stable anti-inflammatory peptide expression quantity is obtained. Through a specific fermented feed formula and a multi-generation directional breeding technology, the zinc enrichment capacity and anti-inflammatory efficiency of maggots are effectively improved, and the maggots become biological resources suitable for the fields of nutritional supplement and medical treatment.

The application discloses a tumor neoantigen detection screening method combined with molecular genomics and calculation structure. The tumor neoantigen detection method disclosed by the application can quickly and efficiently detect tumor neoantigens with high expression, high affinity and stable binding to HLA. The application also discloses a method for predicting the three-dimensional structure of TCR-pMHC protein, which evaluates the affinity and stability of TCR, tumor neoantigen and MHC from the aspect of protein structure, and integrates the affinity and stability prediction of TCR and pMHC, antigen peptide expression translation, hydrophobicity and mutation mode into the detection and analysis process of tumor neoantigen. The application further proposes to use mass spectrometry to verify whether the screened neoantigen really exists in cancer patients, and to evaluate the structural stability of the antigen peptide in the human body. The application further proposes a method and system for predicting the immune cell type and proportion of tumor microenvironment.

The invention provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD6 or related gene and their use for producing L-DOPA from tyrosine and treating dopamine-responsive disorders, such as Parkinson's Disease. The invention also provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD1 and / or CYP76AD6, a nucleic acid encoding a DOPA 4,5-dioxygenase (DOD) enzyme, such as Beta vulgaris DODA1, and, in some cases, a nucleic acid encoding betalain related glucosyltransferase, such as M. jalapa gene cyclo-DOPA 5-O-glucosyltransferase (cDOPA5GT), and their use for producing betalains. Finally, the invention provides chimeric polypeptides, expression vectors, cells, compositions, and organisms, including plants, and their uses in various methods of the invention.

The invention relates to a novel application of a compound, in particular to an application of a red clover extract in preparation of an animal host defense peptide expression promoter. The invention provides an application of a red clover extract in preparation of an animal host defense peptide expression promoter. The application comprises the step of preparing the host defense peptide expression promoter in a required dosage form by taking the red clover extract as a pharmacodynamic active ingredient. Experiments prove that the red clover extract can significantly promote the expression of porcine host defense peptide genes pBD1, pBD2, pBD3, PG1-5, pEP2C, pBD114 and pBD129, and can improve the growth performance of weaned piglets and reduce the diarrhea rate.

The invention relates to an artificial nucleic acid molecule comprising at least one 5′UTR element which is derived from a TOP gene, at least one open reading frame, and preferably at least one histone stem-loop. Optionally the artificial nucleic acid molecule may further comprise, e.g. a poly(A)sequence, a poyladenylation signal, and / or a 3′UTR. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and / or genetic vaccination.

The invention belongs to the technical field of biological medicine and functional food, and discloses a fermentation composition based on signal peptide induction, which is prepared by the following steps: step 1, mixing astragalus membranaceus, lotus leaf, poria cocos and pericarpium citri reticulatae according to the mass ratio of (3-5): (2-4): (2-3): (1-2) to prepare a compound raw material; the fermentation composition is remarkable in effect and multi-target, the food intake can be reduced by reducing mRNA expression of hypothalamus neuropeptide Y and rat-related peptide and increasing the content of glucagon-like peptide-1, lipid metabolism can be regulated and controlled by improving mRNA expression of liver farnesoid X receptors, AMP-dependent protein kinase and carnitine palmitoyl transferase-1, and the food intake can be reduced by increasing the content of glucagon-like peptide-1. The abundance of intestinal bifidobacteria can be improved, and the expression of brown fat heat production related genes is promoted to balance intestinal flora; the safety of the composition is subjected to dual verification of animal and crowd tests, the weight and blood fat indexes of obese rats and obese crowds are remarkably improved, and the liver and kidney functions are not damaged.

The invention discloses an application of a reagent for inhibiting or down-regulating expression of a micropeptide IRIMP in preparation of a tumor radiotherapy sensitizing drug. The invention provides a reagent for inhibiting or down-regulating expression of micropeptide IRIMP, namely siRNA of targeted micropeptide IRIMP, clone formation experiments, apoptosis experiments, cell cycle experiments, comet electrophoresis experiments and immunofluorescence experiments prove that the siRNA of targeted micropeptide IRIMP can significantly inhibit the survival rate of colorectal cancer HCT116 cells after irradiation, the DNA damage degree after irradiation is increased, and the survival rate of colorectal cancer HCT116 cells after irradiation is obviously improved. And the cells are more sensitive to radiation. The siRNA of the targeted micropeptide IRIMP provided by the invention can effectively improve the radiosensitivity of tumor cells in the radiotherapy process, and especially can effectively improve the radiosensitivity of colorectal cancer.

The invention provides cicada slough oligopeptide with antibacterial activity, and the amino acid sequence of the cicada slough oligopeptide is shown as SEQ ID No.1. The cicada slough oligopeptide amino acid sequence is subjected to codon optimization, a target gene is synthesized, a recombinant expression vector is constructed, and the constructed recombinant expression vector is transformed into engineering bacteria to obtain recombinant engineering bacteria; and carrying out amplification culture on the recombinant engineering bacteria, inducing short peptide expression, and separating and purifying an expression product to obtain the purified cicada slough short peptide with antibacterial activity. The invention provides application of the cicada slough oligopeptide with the antibacterial activity. The cicada slough oligopeptide is used for preparing a broad-spectrum antibacterial preparation, a wound dressing, a preparation for protecting the activity of probiotics, a food preservative and a feed additive. The cicada slough oligopeptide is low in production cost, can effectively inhibit the activity of pathogenic bacteria, has the characteristics of high temperature resistance and acid resistance, is high in environmental adaptability, and provides a key material basis for research and development of novel antibacterial products.

The invention relates to a cosmetic or pharmaceutical composition comprising a physiologically acceptable medium and an active principle capable to increase the expression of mitochondrial derived peptide, and more particularly humanin, wherein the active principle can be a peptide, a plant extract such as an aqueous extract of date (Phoenix dactylifera) fruit pulp, an aqueous extract of germinated red clover (Trifolium pratense) seeds, an aqueous extract of quinoa (Chenopodium quinoa) seeds, or an aqueous extract of Iris pallida roots. The invention also concerns a method of cosmetic treatment to protect the skin and the appendages from external aggressions and to combat cutaneous aging.

New insecticidal proteins, nucleotides, peptides, their expression in plants, methods of producing the peptides, new processes, production techniques, new peptides, new formulations, and new organisms, a process which increases the insecticidal peptide production yield from yeast expression systems. The present invention is also related and discloses selected endotoxins we call cysteine rich insecticidal peptides (CRIPS) which are peptides derived from Bacillus thuringiensis (Bt) and their genes and endotoxins in combination with toxic peptides known as Inhibitor Cystine Knot (ICK) genes and peptides as well as with other types of insecticidal peptides such as trypsin modulating oostatic factor (TMOF) peptide sequences used in various formulations and combinations; of both genes and peptides, useful for the control of insects.

This disclosure provides a gene transfer construct comprising a destabilization domain (DD) sequence, a translation separator sequence, and a sequence encoding one or more copies of one or more peptides of interest; a nucleic acid encoding the gene transfer construct; the use of a nucleic acid encoding the gene transfer construct to prevent mitochondrial hyperfission and fragmentation; the use of a nucleic acid encoding the gene transfer construct to induce apoptosis in cells, such as cancer cells; and therapeutic applications of a nucleic acid encoding the gene transfer construct, for example, in the treatment of mitochondrial dysfunction and mitochondrial diseases and disorders associated with various types of cancer.